Unique tumour microenvironment: when ferroptosis activation boosts ICI of liver cancer

Pierluigi Ramadori^#^{1

2}, Suchira Gallage^#^{1

2}, Mathias F Heikenwälder^{3

2}

Affiliations

¹ Division of Chronic Inflammation and Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
² The M3 Research Center, Eberhard Karls University Tübingen, Tübingen, Germany.
³ Division of Chronic Inflammation and Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany m.heikenwaelder@dkfz-heidelberg.de.

^# Contributed equally.

Comment

Pierluigi Ramadori et al. Gut. 2023 Sep.

. 2023 Sep;72(9):1639-1641.

doi: 10.1136/gutjnl-2023-329472. Epub 2023 Jun 15.

Pierluigi Ramadori^#^{1

2}, Suchira Gallage^#^{1

2}, Mathias F Heikenwälder^{3

2}

¹ Division of Chronic Inflammation and Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
² The M3 Research Center, Eberhard Karls University Tübingen, Tübingen, Germany.
³ Division of Chronic Inflammation and Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany m.heikenwaelder@dkfz-heidelberg.de.

^# Contributed equally.

No abstract available

Keywords: CANCER; IMMUNOTHERAPY.

Conflict of interest statement

Competing interests: None declared.

Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade.
Conche C, Finkelmeier F, Pešić M, Nicolas AM, Böttger TW, Kennel KB, Denk D, Ceteci F, Mohs K, Engel E, Canli Ö, Dabiri Y, Peiffer KH, Zeuzem S, Salinas G, Longerich T, Yang H, Greten FR. Conche C, et al. Gut. 2023 Sep;72(9):1774-1782. doi: 10.1136/gutjnl-2022-327909. Epub 2023 Jan 27. Gut. 2023. PMID: 36707233 Free PMC article.